Physician profile
Keely M Staten
NPI 1649758004
$3,049.97
in general payments reported to CMS, 2019-2025
18 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $730 · 2023: $1,143 · 2024: $651 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,140 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,140.06 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $696.70 | 2022-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $465.70 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $364.04 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $359.05 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $230.14 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $216.10 | 2022-2025 | |
| Genzyme Corporation | $191.53 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $137.55 | 2022 | |
| Ucb, INC. | $131.62 | 2022-2023 | Cimzia |
| Incyte Corporation | $102.86 | 2023 | Opzelura |
| Amgen INC. | $25.25 | 2023 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.00 | 2024 | Spevigo |
| Pfizer INC. | $21.82 | 2023 | |
| Paratek Pharmaceuticals, INC. | $18.82 | 2022 | |
| Arcutis Biotherapeutics, INC. | $18.33 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.67 | 2023 | |
| Leo Pharma INC. | $16.69 | 2024 | Adbry |
| Kerecis Limited | $12.10 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keely Staten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.